Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a multi-centre randomised trial of docetaxel with or without AZD6244 in advanced melanoma

BRIEF SUMMARY

A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma.  To determine the efficacy and tolerability of the combination of the selective MEK inhibitor AZD6244 with docetazel in patients with wild-type BRAF metastatic melanoma.

Objectives

Primary:

  • To assess the efficacy of AZD6244 in combination with docetaxel, compared with docetaxel alone, in first line patients with wild type BRAF advanced malignant melanoma.

Secondary:

  • To further assess the efficacy of AZD6244 in combination with docetaxel, compared with docetaxel alone, in first line patients with wild type BRAF advanced malignant melanoma.
  • To assess the safety and tolerability of AZD6244 in combination with docetaxel compared with docetaxel alone.

Our team

  • Sarah Pearson

    OCTO Trial Management Director